For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid endogenous neuropeptide first isolated in 1974 from the cerebral venous blood of sleeping rabbits by the Schoenenberger-Monnier group in Switzerland. Despite its name suggesting a clear mechanism, DSIP's sleep-promoting effects in humans have been contradictory across 40-plus years of research: some controlled trials showed modest sleep improvements, while the most rigorous study (Schneider-Helmert 1992, n=16, double-blind) concluded that short-term treatment of chronic insomnia was not likely to be of major therapeutic benefit. The compound's most compelling human clinical data are actually in addiction medicine: a 1984 uncontrolled study of n=107 inpatients (n=47 alcohol withdrawal, n=60 opiate withdrawal) reported benefits in 97% of opiate-dependent and 87% of alcohol-dependent patients with IV DSIP. In mouse lifespan studies, a DSIP-containing preparation (Deltaran) extended maximum lifespan by 24.1% and reduced spontaneous tumor incidence 2.6-fold. No receptor or precursor gene for DSIP has been identified in 50 years of research.
DSIP (Delta Sleep-Inducing Peptide) is a research compound with no FDA or EMA approval and no accepted clinical use in Western medicine. The compound is distinguished by a fundamental biological mystery: despite 50 years of research, no gene encoding DSIP, no receptor for it, and no precursor protein have been identified. A BLAST search of the DSIP sequence aligns it with a hypothetical protein from Amycolatopsis coloradensis bacteria, suggesting a possible bacterial origin. Whether synthetic DSIP accurately replicates the function of endogenous DSIP-like immunoreactive material in human tissue is an open question given this biological gap.
DSIP has an in vitro half-life of only 15 minutes due to a specific aminopeptidase-like enzyme. In vivo, it is thought to complex with carrier proteins or exist as part of a larger precursor, but neither has been characterized. This instability has been a persistent research obstacle and explains why DSIP analogues with greater stability often show different or stronger effects than the native nonapeptide.
The sleep effects specifically are contested. The compound is named "delta sleep-inducing peptide" based on its discovery context (isolated during rabbit delta sleep states), but human clinical trials have produced inconsistent results. The most rigorous human sleep study (Schneider-Helmert 1992, n=16, double-blind parallel design, polysomnography) concluded that short-term DSIP treatment was not likely of major therapeutic benefit for chronic insomnia, noting that statistically significant effects were weak and possibly attributable to incidental changes in the placebo group. This negative finding in the most controlled study should be stated prominently.
A separate Russian preparation called Deltaran contains DSIP and has been used in limited clinical contexts in Russia, including in children after chemotherapy-induced CNS dysfunction. These applications are not systematically evaluated by Western clinical standards. The geroprotective and antitumor data from animal studies are from the same Russian literature base and have not been independently replicated in Western institutions.
DSIP was first isolated in 1974 by Monnier and Schoenenberger at the University of Basel, Switzerland, from the cerebral venous blood of rabbits in a state of electrically induced sleep. The peptide was characterized by its ability to induce slow-wave (delta) EEG activity and reduce motor activity when infused into the mesodiencephalic ventricle of recipient rabbits, giving it the name delta sleep-inducing peptide.
The nonapeptide has the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). DSIP-like immunoreactivity has been found in the hypothalamus, limbic system, pituitary gland, and peripheral organs including the gut and pancreas, where it co-localizes with glucagon. It is present in human breast milk. Plasma DSIP levels follow a circadian rhythm, peaking in the late afternoon and reaching a trough in early morning. DSIP-like immunoreactivity decreases at the transition from wakefulness to sleep in young men, consistent with a role in sleep initiation, though the causality direction is unclear.
The biological status of DSIP remains uniquely mysterious among established neuropeptides. No gene encoding DSIP has been identified in any species, no precursor protein has been characterized, and no receptor has been cloned or identified. This is extremely unusual for a peptide with 50 years of documented biological activity. The alignment of DSIP sequence with a hypothetical bacterial protein raises questions about whether DSIP is a classical neuropeptide or whether its biological activities arise through a different mechanism altogether, such as interaction with existing receptors (NMDA, opioid, GABA-A) without being the endogenous ligand.
Research interest in DSIP has expanded well beyond sleep. The compound has documented effects on stress hormone systems (decreasing ACTH, blocking CRF-induced corticosterone release), neuroendocrine function (stimulating LH, GH release, inhibiting somatostatin), and has demonstrated antinociceptive, antioxidant, and anticonvulsant effects in animal models. The Russian Deltaran preparation, containing DSIP, has been evaluated in several small clinical studies including for diabetes management in the elderly and for post-chemotherapy CNS recovery in children.
DSIP's mechanism of action remains incompletely characterized after 50 years, partly because no dedicated DSIP receptor has been identified. The peptide appears to exert effects through multiple receptor systems rather than a single defined pathway.
NMDA receptor modulation: DSIP blocks NMDA receptor-activated responses in cortical areas. NMDA receptors are critical mediators of excitatory neurotransmission, learning, and memory. Blocking excessive NMDA receptor activity is associated with reduced neuronal hyperexcitability, anticonvulsant effects, and neuroprotection. The sleep-inducing effect in the median thalamus is suppressed by naloxone, suggesting interaction with opioid receptor systems, but DSIP does not bind directly to opioid receptors in classical binding assays. Instead, it appears to stimulate immunoreactive met-enkephalin release indirectly, raising endogenous opioid activity.
GABA potentiation: DSIP enhances GABA-activated currents in hippocampal and cerebellar neurons. GABA is the primary inhibitory neurotransmitter; its potentiation reduces neuronal excitability and contributes to sedation, anxiolysis, and anticonvulsant effects. This GABA-potentiating mechanism, combined with NMDA blockade, positions DSIP as a modulator of the excitatory-inhibitory balance in key brain regions without being a direct agonist at either receptor type.
Stress hormone modulation: DSIP decreases basal corticotropin (ACTH) levels and blocks CRF-induced corticosterone release. This glucocorticoid-modulating action is mechanistically relevant to the compound's described stress-limiting effects. DSIP is also homologous to glucocorticoid-induced leucine zipper (GILZ), a protein involved in the MAPK/ERK cascade and adipogenesis, providing a molecular explanation for metabolic effects.
GH axis effects: DSIP stimulates somatoliberin (GHRH) release and somatotrophin (GH) secretion while inhibiting somatostatin release. This disinhibition of the GH axis is consistent with growth hormone's role in slow-wave sleep and provides a plausible indirect mechanism for sleep-promoting effects: enhanced GH pulsatility during the night would be expected to reinforce slow-wave sleep architecture.
Antioxidant effects: Multiple Russian studies have documented that DSIP and Deltaran increase the activity of superoxide dismutase, catalase, and ceruloplasmin in rat tissues. Enhanced enzymatic antioxidant defense is proposed as a primary mechanism for the geroprotective effects observed in lifespan studies. One 2011 study (Bondarenko et al., Advances in Gerontology) specifically characterized this as the mechanism of geroprotective action.
The circadian context: plasma DSIP levels peak in the late afternoon and trough in early morning. DSIP-like immunoreactivity decreases during the sleep-wake transition. This circadian patterning is consistent with DSIP playing a modulatory role in sleep initiation and architecture, even if the precise receptor-mediated mechanism remains unresolved.
The 1981 study in 6 healthy volunteers found that IV DSIP increased total sleep time by 59% in a 130-minute interval after treatment compared to placebo. Subjects reported an immediate feeling of sleep pressure. Delayed effects on subsequent night sleep were shorter sleep onset, reduced stage 1 percentage, and better sleep efficiency. Notably, EEG analysis revealed no sedation in the classic pharmacological sense (no slowing of waking EEG, no hangover).
The 1984 insomnia studies (n=10 combined across two trials) reported statistically significant improvements in sleep efficiency, sleep arousals, REM sleep percentage, spindle frequency, and slow-wave sleep percentage.
The 1992 Schneider-Helmert double-blind study, the most methodologically rigorous sleep trial, produced an important negative result. While DSIP showed higher sleep efficiency and shorter sleep latency versus placebo, the author's conclusion was that short-term treatment of chronic insomnia with DSIP was not likely to be of major therapeutic benefit. The statistical effects were described as weak and possibly attributable to incidental changes in the placebo group. None of the subjective sleep quality measures showed significant change.
The contradiction between the 1981 to 1984 positive findings and the 1992 negative conclusion likely reflects differences in study rigor. The 1981 to 1984 studies were smaller (n=6 and n=10 combined) while the 1992 study used a more rigorous double-blind parallel design. Some researchers have proposed that DSIP may work better at specific circadian phases, explaining the variable results, but this hypothesis has not been systematically tested.
The sleep evidence for DSIP is genuinely contradictory. Early small trials showed promising signals; the most rigorous trial concluded the compound is unlikely to be of major therapeutic benefit for chronic insomnia. The compound is named for sleep induction but the evidence base for that use is weaker than its name implies. The 1992 negative conclusion in a double-blind design carries more weight than the earlier positive findings from smaller, less rigorous trials.
The Dick et al. 1984 study administered IV DSIP to 107 inpatients presenting with withdrawal symptoms: 47 with alcohol withdrawal and 60 with opiate withdrawal. The reported results were striking: DSIP treatment alleviated withdrawal symptoms in 97% of opiate-dependent patients and 87% of alcohol-dependent patients. No major adverse effects were reported. The mechanism proposed was DSIP's postulated agonistic activity at opiate receptors, based on animal research by Tissot showing DSIP's sleep effects were reversed by naloxone.
The Scherbaum 1983 study in 49 evaluable patients (28 alcohol, 39 opiate withdrawal) reported that 48 out of 49 patients showed a beneficial effect of DSIP, with an immediate onset of action and good, lasting suspension of somatic symptoms and signs. Anxiety resolved more slowly, within hours. No major adverse effects occurred.
These results would be remarkable if validated in a placebo-controlled trial. The critical limitation is that neither study included a placebo control group. Withdrawal syndromes have substantial spontaneous resolution rates within the time frames studied, and the power of expectation effects in addiction medicine is well-documented. The studies were conducted in the same era (1983 to 1984) by groups with close ties to the original DSIP discovery team. No independent replication of these withdrawal findings appears in indexed Western literature in the subsequent 40 years. The 97% and 87% response rates, if genuine, would be transformative for addiction medicine. They have not been followed up with controlled trials.
The withdrawal data represent the most numerically striking human clinical findings in the DSIP literature, and potentially the most clinically important application if validated. The limitation is absolute: no placebo control, no blinding, 40-year absence of follow-up trials from any independent group. A 97% response rate in opiate withdrawal without a control arm is clinically uninterpretable because withdrawal has natural resolution timelines and strong expectation effects. This application warrants a controlled trial that has never been conducted.
The Popovich et al. 2003 study administered Deltaran (a DSIP-containing preparation) subcutaneously to female SHR mice in 5-day monthly courses from age 2 months until natural death. The results: total spontaneous tumor incidence decreased 2.6-fold; chromosome aberrations in bone marrow cells decreased by 22.6%; age-related switching-off of estrous function was slowed; and maximum lifespan in the last 10% of survivors (the oldest animals) increased by 24.1% compared to controls.
These are striking results for a longevity intervention. A 2.6-fold reduction in spontaneous tumor incidence combined with a 24.1% increase in maximum lifespan would position Deltaran/DSIP among the most effective geroprotective interventions studied in mice. The study was conducted by Popovich and Anisimov, the same group behind much of the Epithalon and Russian bioregulator lifespan research.
The Bondarenko 2011 Advances in Gerontology paper proposed the mechanism: DSIP increases superoxide dismutase, catalase, and ceruloplasmin activity, particularly in late ontogenesis. Enhanced antioxidant defense would be consistent with reduced oxidative damage to DNA (explaining the chromosome aberration reduction) and reduced oncogenic transformation rates (explaining the tumor reduction).
The geroprotective data are exclusively from Russian rodent studies and have not been replicated by independent Western institutions. The use of Deltaran (a preparation) rather than pure synthetic DSIP introduces uncertainty about which components are driving the effects. SHR mice are a specific strain (spontaneously hypertensive) that may not generalize to all aging contexts.
The lifespan and antitumor data are among the most striking in any peptide geroprotection literature: a 2.6-fold tumor reduction and 24.1% maximum lifespan extension would be extraordinary if replicated. They have not been replicated independently in 20-plus years. They come from the same Russian research ecosystem that produced the Epithalon and Thymalin lifespan claims (similarly unreplicated). The antioxidant mechanism characterization is coherent and testable but the primary finding awaits independent confirmation.
A series of five trials published in European Neurology in 1983 administered IV DSIP to healthy subjects and evaluated subjective stress tolerance. The reported outcomes were "better relaxation" and "apparently improved tolerance against psychic stress." These studies were conducted by the Schoenenberger group and involved small numbers of subjects.
Animal research has provided the mechanistic underpinning: DSIP decreases basal corticotropin (ACTH) levels, blocks CRF-induced corticosterone release, and in 1992 rat experiments, increased hypothalamic substance P concentration with "sharp decreases in classical manifestations of stress." Sudakov et al. (1995) specifically characterized DSIP's role in emotional stress resistance, proposing it as a stress-limiting peptide.
The neuroendocrine effects are mechanistically interesting: DSIP stimulates LH release, stimulates GH secretion via GHRH stimulation and somatostatin inhibition, and reduces ACTH and corticosterone. This pattern, reducing the HPA stress axis while augmenting the GH-somatotropic axis, is consistent with a restorative or anti-stress neuroendocrine profile.
The cortisol-reducing data have direct clinical interest for high-stress individuals and for conditions where HPA axis dysregulation is prominent (PTSD, burnout, major depression). However, the human data are all from the 1983 to 1985 era with small samples, and no modern controlled study has examined DSIP's effects on HPA axis function with validated biochemical endpoints.
The stress modulation data have a coherent mechanistic basis (ACTH reduction, CRF blocking, substance P elevation) and a directional human signal from small 1980s trials. The neuroendocrine effect profile, reducing HPA axis while augmenting somatotropic axis, is pharmacologically attractive. All mechanistic data are from animal studies; human evidence is limited to small subjective reports from 40 years ago with no modern replication.
The Deltaran post-chemotherapy study in 10 children (aged 3 to 16) found that chemotherapy-induced impairment in bioelectrical activity of the brain was reduced in 9 out of 10 children following a 10-day Deltaran course. This is a small uncontrolled clinical observation but involves a population (pediatric cancer patients) with real clinical need for CNS recovery approaches and limited available interventions. The primary Russian publication is not widely accessible in English.
The 2021 Sazonov et al. Molecules paper tested intranasal DSIP in a rat MCAO stroke model at 120 mcg/kg, administered preventively before occlusion and then for 7 days post-reperfusion. DSIP treatment produced significant improvement in motor coordination (rotarod performance) at 14 and 21 days post-stroke compared to vehicle controls. Infarction volume was also assessed. An important safety note from this paper: in a prior study by the same group, DSIP administered during the occlusion period itself caused animal mortality, possibly through inactivation of c-Fos early response genes linked to NMDA receptor activation during ischemia. The 2021 positive results were achieved specifically by avoiding administration during active occlusion.
The NMDA receptor-blocking properties of DSIP provide a mechanistic basis for neuroprotection: NMDA receptor overactivation (excitotoxicity) is a major driver of ischemic neuronal death. An NMDA blocker administered before or after (but not during) stroke would be predicted to reduce ischemic damage.
The stroke rat data are the most recent indexed mechanistic neuroprotection study for DSIP and provide specific safety context (timing matters: administration during ischemia may be harmful, while pre-treatment and post-reperfusion treatment improves outcomes). The pediatric chemotherapy observation is compelling in clinical context but is an n=10 uncontrolled Russian-language series. Neither has been followed up with human trials.
Delta sleep-inducing peptide. 100mcg before bed. Inconsistent results in human trials.
Human dose is well-established from published IV trials at 25 nmol/kg body weight, approximately 20 to 25 mcg/kg or roughly 1.5 to 2 mg total for a 70 to 80 kg person. However, IV infusion pharmacokinetics differ fundamentally from subcutaneous injection. DSIP's 15-minute in vitro half-life means that SQ injection likely produces very different plasma concentration curves and tissue distribution compared to the slow IV infusions used in all published trials. The doses shown (100 to 500 mcg SQ) reflect common community protocols that have no pharmacokinetic validation from published research.
Among sleep-related peptides, DSIP is unique in being truly endogenous (found in human tissue, breast milk, and plasma with circadian rhythm) whereas most sleep peptides either modulate established receptors (melatonin at MT1/MT2, orexin antagonists at OX1R/OX2R) or are growth hormone secretagogues with secondary sleep effects. The comparison to melatonin is informative: melatonin regulates sleep timing through circadian mechanisms, while DSIP was proposed to regulate sleep quality and depth through different mechanisms. The difference in evidence quality is stark: melatonin has extensive Phase 3 RCT data and regulatory approval for jet lag and shift work, while DSIP has contradictory small trials. Within the peptide research field, DSIP is often mentioned alongside Selank and Semax as stress-modulating neuropeptides. Semax has Russian regulatory approval and BDNF-upregulating mechanisms well-characterized in animal models with some human observational data. Selank has a similar regulatory status. DSIP predates both and has more human trial data by volume, but none of those trials used modern clinical trial methodology. The Deltaran preparation used in Russian longevity and geroprotection research occupies a similar position to the Khavinson bioregulators: Russian clinical use without Western-standard controlled trials.
The human safety record for DSIP is sparse by volume but generally favorable across the trials conducted. In all published human studies, no major adverse effects were reported.
The 1981 Schneider-Helmert first-in-human study (n=6 healthy volunteers, IV 25 nmol/kg) reported no sedation in the classic pharmacological sense, no adverse effects, and notably no "hangover" effect despite the increase in sleep. The 1992 Schneider-Helmert double-blind study (n=16 chronic insomniacs, IV 25 nmol/kg for 3 consecutive afternoons) also reported no adverse effects.
The Dick et al. 1984 withdrawal study (n=107 patients) reported no major adverse effects across both alcoholic and opiate-dependent patients receiving IV DSIP.
One important safety signal from a different context: a study of DSIP as an adjunct to isoflurane anaesthesia found that it actually increased heart rate and reduced depth of anaesthesia rather than deepening it as expected. This paradoxical effect in the anaesthetic context suggests that DSIP's interaction with sedation mechanisms is not straightforwardly additive with anaesthetic agents and could be a concern in surgical settings.
Because DSIP has a very short in vitro half-life (approximately 15 minutes) and is thought to be rapidly degraded and carrier-protein-complexed in vivo, accumulation with repeated dosing is unlikely, but this has not been formally characterized.
Long-term safety of DSIP in humans is entirely unknown. No chronic dosing study has been published. The self-experimentation community typically uses subcutaneous injection protocols at extrapolated doses, but no systematic adverse event tracking exists for this use. Interaction with anaesthetics, opioid medications, and benzodiazepines cannot be ruled out given DSIP's interactions with all of these systems' receptor targets.
DSIP occupies a peculiar position in the peptide landscape: it is one of the oldest and most widely studied neuropeptides (discovered 1974, thousands of papers), yet it is also one of the least mechanistically understood (no receptor, no gene, no precursor in 50 years) and has the weakest translation from animal to human.
The compound's name is both its biggest marketing asset and its most misleading attribute. "Delta sleep-inducing" implies a clear, proven sleep effect. The most rigorous human sleep trial (Schneider-Helmert 1992, n=16, double-blind) concluded that DSIP is not likely of major therapeutic benefit for chronic insomnia. The earlier positive findings in smaller trials carry less evidentiary weight.
Where DSIP is more interesting is where its name doesn't suggest anything: the withdrawal medicine data (uncontrolled but striking), the geroprotective lifespan effects in mice (unreplicated but dramatic), and the mechanistic stress hormone modulation (coherent neuroendocrine profile). These applications have been largely ignored in favor of the sleep angle, possibly because the name drives commercial interest in that direction.
The fundamental scientific gaps, no receptor, no gene, a possible bacterial origin of the sequence, contradictory species results, short in vitro half-life, are real obstacles to serious therapeutic development. This is not a compound like Semax or Pinealon where the research program is coherent and growing. DSIP has been stalled for decades at the level of suggestive but inconclusive small trials and animal studies.
For sleep specifically, DSIP should not be promoted as a peptide sleep aid on the basis of the evidence record. The best controlled study says otherwise. For withdrawal medicine and for geroprotection, the data are interesting enough to warrant controlled trial follow-up that has not happened in 40-plus years.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use